strontium has been researched along with docetaxel anhydrous in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, LJ; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Daunton, A; Goranitis, I; Hussain, S; James, ND; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, SJ; Pope, AM; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
1 review(s) available for strontium and docetaxel anhydrous
| Article | Year |
|---|---|
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
1 trial(s) available for strontium and docetaxel anhydrous
| Article | Year |
|---|---|
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Strontium; Taxoids; Zoledronic Acid | 2016 |